Here are five points:
1. NuVasive accounts for 0.3 percent of Quantitative Systematic Strategies’ holdings.
2. The firm has an average rating of “buy” and an average target price of $58.54.
3. The company’s 50-day moving average is $47.93, and its 200-day moving average is $50.81.
4. NuVasive has a 52-week low of $36.81 and a 52-week high of $56.61.
5. The firm has a market capitalization of $1.94 billion.
More articles on devices:
43 spine, orthopedic devices receive FDA 510(k) clearance in January
Foot and ankle market to reach $5.4B in 2020 — 4 insights
Wright Medical Group shares receive average price target of $28.11: 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
